FROM:
Description
Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis
READ MORE >
Company Snapshot
Status
Live
Dealing Restrictions
None
Price
16.00
Ticker
REDX
Class
ORD
Settlement
Crest
Industry
Professional, scientific & technical services
COUNTRY
United Kingdom
Company Number
07368089
ISIN
GB00BSNB6S51
Currency
GBX
COMPANY INSIGHTS
Incorporated
7 September 2010
Securities in Issue
334.91m
Market Cap
£47,880,632.48
key features of trading on jp jenkins
BUYERS
Buyers decide on the price per share they’re willing to pay, and the number of shares they wish to buy.
SELLERS
Sellers decide the minimum price they’ll accept for their shares.
IMPORTANT INFORMATION
This instruments from Redx Pharma Ltd is not traded on an investment exchange such as the London Stock Exchange or the Alternative Investment Market. Consequently, transactions involving these instruments may be infrequent, potentially causing a delay between when you give instructions to buy or sell and when your order is executed. Additionally, it can be challenging to accurately assess the value of your investment.
Download Area
| Documents | ||
| Annual Accounts 2023 | 11.99 MB |
Description
Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis
READ MORE >
Latest News
SEE MORE NEWS ARTICLES >
Redx Pharma Ltd Management Information
Dr Jane Griffiths
Chair
Lisa LM Anson
Chief Executive Officer
Andrew Booth
Group Financial Controller
Peter Collum
Chief Financial Officer
Peter Presland
Non-Executive Director
Dr Bernhard Kirschbaum
Non-Executive Director
Dr Claire Catherinet
Non-Executive Director
Natalie Berner
Non-Executive Director
Dr Robert Scott MD
Non-Executive Director
Redx Pharma Ltd Contact Details
Address
Redx Pharma Plc
Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG
UK
Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG
UK
EMAIL
info@redxpharma.com
phone
+44 (0)1625 469900
Contacts
Investor Relations
Redx Investor Relations
Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG
UK
Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG
UK
ir@redxpharma.com
Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK
TRANSACTING ON JP JENKINS
‘Trading‘ on JP Jenkins is done via a matched bargain facility, this means that on instruction from your ‘Broker’ we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you
